STAT+: Alnylam to partner with Inceptive Nucleics for AI foundation models for RNAi therapeutics

Jakob Uszkoreit went from inventing the “T” in Chat GPT to putting the “AI” in Alnylam’s RNAi therapeutics. After over a dozen years at Google, where he’d co-authored the seminal “Attention is all you need” paper that laid the foundations for artificial intelligence models like GPT, Uszkoreit in 2021 left a job at Google Brain to start Inceptive Nucleics. The company is building “AI foundation models of life” — models that will hopefully learn so much about how biology operates that they will be reusable across many different tasks without having to be trained specifically to do them.  On Wednesday, Alnylam and Inceptive announced a new, three-year strategic collaboration worth up to $2 billion, with $30 million upfront in cash and equity in the startup. The additional payments will be predicated on the co-discovered drugs achieving preclinical, regulatory, and commercial sales milestones. In 2025, Alnylam’s total revenues were $3.7 billion. Continue to STAT+ to read the full story…